Want to see REVB full AI Analyst Report?
REVB Stock Chart & Stats
$1.06
$0.04(3.50%)
At close: 4:00 PM EDT
$1.06
$0.04(3.50%)
Day’s Range― - ―
52-Week Range$0.88 - $11.72
Previous CloseN/A
Volume6.03K
Average Volume (3M)740.56K
Market Cap
$4.54M
Enterprise Value-$6.80
Total Cash (Recent Filing)$11.48M
Total Debt (Recent Filing)$739.92K
Price to Earnings (P/E)―
Beta0.73
Next Earnings
Nov 05, 2026EPS Estimate
-0.88Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-7.00
Shares Outstanding3,983,416
10 Day Avg. Volume239,834
30 Day Avg. Volume740,557
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.22
Price to Sales (P/S)0.00
P/FCF Ratio-0.24
Enterprise Value/Market Cap>-0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$16.00Price Target Upside1409.43% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-5.2
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage And Stronger Equity BaseLow debt levels and a materially improved equity base reduce near-term solvency pressure and give management more optionality on financing and partnerships. This structural balance-sheet strength supports continued R&D investment without immediate default risk, improving strategic flexibility.
Focused Clinical-stage Innate-immunity PipelineA specialized focus on innate immunity creates a clear, differentiated scientific niche and positions the company in areas with high unmet need. If clinical validation is achieved, this durable therapeutic specialization can yield high barriers to entry and attractive long-term licensing or partnership opportunities.
Strengthened Management And GovernanceEnhanced executive contracts and active board actions signal management retention and governance readiness to manage capital structure and M&A outcomes. These durable governance steps help maintain continuity through development programs and support coordinated strategic decisions over coming quarters.
Bears Say
Pre-revenue Status With Persistent LossesThe company remains pre-revenue with sizable and persistent net losses, meaning there is no current commercial cash inflow to offset R&D spend. Over a multi-month horizon this limits internal runway and makes progress dependent on successful clinical outcomes or external funding events.
Sustained Negative Operating Cash FlowConsistent negative operating and free cash flow indicate ongoing cash burn that will likely require external financing or partnerships. Reliance on new capital raises risks dilution and can constrain long-term R&D timelines if market access to funding tightens over the next several quarters.
Negative Returns On EquityAlthough equity has improved, negative ROE shows shareholder capital is not generating profits and current investments aren't delivering returns. This structural weakness raises the risk of further financing-driven dilution or strategic shifts until clinical progress translates into value creation.
Revelation Biosciences News
REVB FAQ
What was Revelation Biosciences’s price range in the past 12 months?
Revelation Biosciences lowest stock price was $0.88 and its highest was $11.72 in the past 12 months.
What is Revelation Biosciences’s market cap?
Revelation Biosciences’s market cap is $4.54M.
When is Revelation Biosciences’s upcoming earnings report date?
Revelation Biosciences’s upcoming earnings report date is Nov 05, 2026 which is in 86 days.
How were Revelation Biosciences’s earnings last quarter?
Revelation Biosciences released its earnings results on Aug 06, 2026. The company reported -$0.87 earnings per share for the quarter, beating the consensus estimate of -$0.875 by $0.005.
Is Revelation Biosciences overvalued?
According to Wall Street analysts Revelation Biosciences’s price is currently Undervalued.
Does Revelation Biosciences pay dividends?
Revelation Biosciences does not currently pay dividends.
What is Revelation Biosciences’s EPS estimate?
Revelation Biosciences’s EPS estimate is -0.88.
How many shares outstanding does Revelation Biosciences have?
Revelation Biosciences has 3,983,416 shares outstanding.
What happened to Revelation Biosciences’s price movement after its last earnings report?
Revelation Biosciences reported an EPS of -$0.87 in its last earnings report, beating expectations of -$0.875. Following the earnings report the stock price went up 1.786%.
Which hedge fund is a major shareholder of Revelation Biosciences?
Currently, no hedge funds are holding shares in REVB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Revelation Biosciences
Revelation Biosciences, Inc. is a biopharmaceutical firm currently in its clinical development phase, dedicated to the advancement and commercialization of treatments and diagnostic tools targeting the immune system. The company's therapeutic pipeline includes promising candidates such as GEM-AKI, which is being developed as a potential therapy for both the prevention and management of acute kidney injury, and GEM-CKD, intended for the prevention and treatment of chronic kidney disease. Established in 2019, this San Diego, California-based enterprise was formerly known as Petra Acquisition, Inc., before officially adopting the name Revelation Biosciences, Inc. in January 2022.
REVB Stock 12 Month Forecast
Average Price Target
$16.00
▲(1409.43% Upside)
Technical Analysis
GT Biopharma
―
Dermata Therapeutics
―
CERo Therapeutics Holdings
―
Psyence Biomedical
―
Azitra Inc
―
Ownership Overview
8.65% Insiders
0.68% Mutual Funds
10.61% Other Institutional Investors
80.06% Public Companies and
Individual Investors